Probing the Role of Chaperone-TPR Complexes in Tau Proteostasis
探讨分子伴侣-TPR 复合物在 Tau 蛋白质稳态中的作用
基本信息
- 批准号:10029781
- 负责人:
- 金额:$ 224.04万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAnimalsArchitectureAttentionBindingBinding SitesBiochemicalBrainC-terminalCellsChemicalsClientCollaborationsComplexCryoelectron MicroscopyCrystallographyDevelopmentDiseaseEngineeringEnsureEnzymesEquilibriumFK506 binding protein 5GeneticGoalsHeat-Shock Proteins 70Heat-Shock Proteins 90IndividualLaboratoriesLearningLibrariesLocationMAPT geneMapsMeasuresModelingModificationMolecularMolecular ChaperonesNerve DegenerationNeurodegenerative DisordersNeurofibrillary TanglesNeuronsPP5 protein-serine-threonine phosphatasePathologicPeptide LibraryPeptide antibodiesPeptidylprolyl IsomerasePhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPlayPost-Translational Protein ProcessingProcessProgressive Supranuclear PalsyProline-Rich DomainProtein phosphataseProteinsProteomicsQuality ControlRoleScanningSolubilityStructureTauopathiesTertiary Protein StructureTimeUbiquitinationWorkbasecombinatorialcorticobasal degenerationdesignimprovedinhibitor/antagonistinnovationnew therapeutic targetnovel therapeuticsprotein aminoacid sequenceprotein protein interactionproteostasisrecruittau Proteinstau aggregationtau conformationtau phosphorylationtissue-factor-pathway inhibitor 2ubiquitin-protein ligase
项目摘要
Abstract. A devastating class of untreatable, neurodegenerative disorders, which includes progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD) and Alzheimer’s disease (AD), are associated with
accumulation of neurofibrillary tangles (NFTs) in the brain. These aggregates are primarily composed of
microtubule-associated protein tau (MAPT/tau), which is heavily modified by post-translational modifications
(PTMs). If we understood how neurons normally regulate tau’s PTMs, we might be able to find ways of restoring
its delicate balance. The objective of this project is to understand how the molecular chaperones, heat shock
protein 70 (Hsp70) and heat shock protein 90 (Hsp90), direct modifications on tau. Hsp70 and Hsp90 are known
to bind key, aggregation-prone locations in tau. While these interactions improve the solubility of tau, they also
recruit a number of critical PTM enzymes including: (i) the E3 ubiquitin ligase CHIP, (ii) the cis-trans prolyl
isomerase FKBP51 and (iii) the protein phosphatase PP5. Specifically, each of these enzymes contains a
tetratricopeptide repeat (TPR) domain, which has affinity for the conserved EEVD-CO2H motif at the C-termini
of Hsp70 and Hsp90. Thus, we hypothesize that complexes between chaperones and TPR domains ultimately
determines tau’s conformation and whether it is ubiquitinated or de-phosphorylated. Thanks to innovations in
cryo-EM and recent breakthroughs in large-scale peptide libraries and antibody design, we are poised to use
structural and chemical approaches to understand how chaperones coordinate with TPR proteins to modify tau.
In preliminary studies, we have measured binding of the chaperone’s EEVD motifs to a panel of TPR domains,
revealing unexpected selectivity of Hsp70 for PP5 and Hsp90 for FKBP51, as well as a key role for
phosphorylation in tuning these affinities. We have also created a library of ~640,000 peptide sequences and
used it to identify a potent (<10 nM) inhibitor of CHIP’s TPR domain that does not bind closely related TPRs.
Finally, we have validated a structural approach to studying the Hsp70-CHIP-tau ternary complex, a project
which has already uncovered a surprising, essential role for ADP. Guided by these exciting findings and fueled
by a team-based approach, we propose to study how tau interacts with: (SA1) Hsp70/Hsp90-CHIP, (SA2)
Hsp90-FKBP51 and (SA3) Hsp70-PP5. Through this effort, we aim to determine how molecular switches at the
key protein interfaces tune the structure and modifications on tau. We anticipate that these studies could also
revealing new drug targets for treating tauopathies.
抽象的。一类毁灭性的无法治疗的神经退行性疾病,包括进行性的
核上性瘫痪(PSP)、皮质基底膜变性(CBD)和阿尔茨海默病(AD)与
神经原纤维缠结(NFT)在大脑中的积累。这些集合体主要由以下组成
微管相关蛋白tau(MAPT/tau),被翻译后修饰严重修饰
(PTMS)。如果我们了解神经元通常是如何调节tau的PTM的,我们或许能够找到恢复
它微妙的平衡。这个项目的目标是了解分子伴侣、热休克
蛋白质70(Hsp70)和热休克蛋白90(Hsp90)直接修饰tau。HSP70和HSP90是已知的
在tau中绑定关键的、易于聚合的位置。虽然这些相互作用提高了tau的溶解度,但它们也
招募一些关键的PTM酶,包括:(I)E3泛素连接酶芯片,(Ii)顺-反式Pro
异构酶FKBP51和(Iii)蛋白磷酸酶PP5。具体来说,这些酶中的每一种都含有一种
四肽重复(TPR)结构域,与C末端保守的EEVD-CO2H基序有亲和力
Hsp70和Hsp90的同源性。因此,我们假设伴侣和TPR结构域之间的复合体最终
决定tau的构象以及它是泛素化还是去磷酸化。得益于
冷冻-EM和最近在大规模多肽库和抗体设计方面的突破,我们准备使用
结构和化学方法,以了解伴侣如何与TPR蛋白协调来修饰tau。
在初步研究中,我们测量了伴侣的EEVD基序与一组TPR结构域的结合,
揭示了Hsp70对PP5和Hsp90对FKBP51的意外选择性,以及Hsp70对PP5的关键作用
调节这些亲和力的磷酸化。我们还创建了一个包含约64万个肽序列的文库,并
用它来鉴定芯片的TPR结构域的一个有效的(<;10 nM)抑制物,它不能结合密切相关的TPR。
最后,我们验证了一种研究Hsp70-芯片-tau三元复合体的结构方法,这是一个项目
这已经揭示了ADP令人惊讶的、至关重要的作用。在这些令人兴奋的发现的指导下,
通过基于团队的方法,我们建议研究tau如何与:(SA1)HSP70/HSP90-CHIP,(SA2)
HSP90-FKBP51和(SA3)HSP70-PP5。通过这项努力,我们的目标是确定分子开关在
关键的蛋白质接口调节tau的结构和修饰。我们预计这些研究还可以
揭示治疗紧张症的新药物靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles Scott Craik其他文献
Charles Scott Craik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles Scott Craik', 18)}}的其他基金
Developing Antivirals Targeting Proteases and Polymerases of Coronaviruses, Picornaviruses and Bunyavirales
开发针对冠状病毒、小核糖核酸病毒和布尼亚病毒的蛋白酶和聚合酶的抗病毒药物
- 批准号:
10512628 - 财政年份:2022
- 资助金额:
$ 224.04万 - 项目类别:
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity
开发新的放射性示踪剂来研究免疫细胞动员颗粒酶蛋白水解活性
- 批准号:
10231735 - 财政年份:2021
- 资助金额:
$ 224.04万 - 项目类别:
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity
开发新的放射性示踪剂来研究免疫细胞动员颗粒酶蛋白水解活性
- 批准号:
10395587 - 财政年份:2021
- 资助金额:
$ 224.04万 - 项目类别:
New radiotracer development to study immune cell mobilization of granzyme proteolytic activity
开发新的放射性示踪剂来研究免疫细胞动员颗粒酶蛋白水解活性
- 批准号:
10591415 - 财政年份:2021
- 资助金额:
$ 224.04万 - 项目类别:
Non-invasive Differentiation of Benign Lesions from Aggressive Pancreatic Cancer
良性病变与侵袭性胰腺癌的无创鉴别
- 批准号:
8823694 - 财政年份:2015
- 资助金额:
$ 224.04万 - 项目类别:
Extracellular Proteolysis as a Molecular Stratification Tool for Cancer
细胞外蛋白水解作为癌症的分子分层工具
- 批准号:
8829207 - 财政年份:2014
- 资助金额:
$ 224.04万 - 项目类别:
Antibodies for Characterizing the Structure and Function of Proteases
用于表征蛋白酶结构和功能的抗体
- 批准号:
8702411 - 财政年份:2014
- 资助金额:
$ 224.04万 - 项目类别:
Allosteric Inhibition of a Family of Proteolytic Enzymes
蛋白水解酶家族的变构抑制
- 批准号:
8577916 - 财政年份:2013
- 资助金额:
$ 224.04万 - 项目类别:
Allosteric Inhibition of a Family of Proteolytic Enzymes
蛋白水解酶家族的变构抑制
- 批准号:
8698774 - 财政年份:2013
- 资助金额:
$ 224.04万 - 项目类别:
Allosteric Inhibition of a Family of Proteolytic Enzymes
蛋白水解酶家族的变构抑制
- 批准号:
9039629 - 财政年份:2013
- 资助金额:
$ 224.04万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 224.04万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 224.04万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 224.04万 - 项目类别: